Decode Age, a science‑led longevity organisation pioneering ageing biology, biomarker research, and gut microbiome science, has raised ₹14.48 crore in its Pre‑Series A funding round. The round was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited, a veteran with over four decades of leadership in pharmaceutical innovation, scale, and manufacturing excellence.
This investment strengthens Decode Age’s mission to make the biology of ageing measurable, understandable, and actionable through a comprehensive, science‑driven longevity ecosystem centred on the gut microbiome.
Building India’s Most Advanced Longevity Research Platform
Decode Age has developed a robust longevity research infrastructure that integrates:
- Multi‑omics testing
- Biomarker discovery programmes
- Whole‑genome gut microbiome analysis
- Precision‑based interventions and formulations
At the core of this ecosystem is one of India’s most advanced whole‑genome microbiome analysis systems, offering high‑resolution insights into microbial diversity and its influence on immunity, metabolism, inflammation, and ageing pathways.
Decode Age’s laboratory workflows prioritise precision, reproducibility, and scientific rigour, supporting researchers, clinicians, and individuals seeking deeper biological understanding and practical tools for healthy ageing.
Advancing Research‑Driven Longevity Solutions
Using insights from ageing biology and microbiome science, Decode Age is developing a new generation of research‑driven supplements and longevity interventions. These solutions are designed to support biological pathways associated with:
- Cellular energy and mitochondrial function
- Metabolic balance
- Inflammatory regulation
- Cognitive resilience
- Age‑related conditions such as cancer, dementia, and chronic diseases
The new capital will accelerate:
- Expansion of biomarker discovery programmes
- Advancement of multi‑omics and microbiome research pipelines
- Strengthening of scientific and analytical infrastructure
- Formulation research aligned with the hallmarks of ageing
- Deeper collaborations across India’s and the world’s longevity ecosystem
Parth Amin, CEO & Co‑Founder, Decode Age, said: “This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology. The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes, and build the scientific infrastructure that drives our work. We remain committed to translating rigorous science into insights that help individuals make informed decisions about their long‑term health.”
Dr Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited, added: “Decode Age is advancing an area of science that will redefine how we think about health, disease, and ageing. Their capabilities in gut microbiome research and ageing biology are rigorous and forward‑looking, offering individuals and clinicians biological insights that were previously inaccessible. This investment reflects my confidence in their scientific vision and the long‑term impact they aim to create.”
Strengthening India’s Position in Global Longevity Science
Decode Age is building a world‑class scientific, clinical, and product team to take India’s longevity innovation to a global audience. The company aims to position India as a leader in:
- Microbiome science
- Healthy ageing research
- Translational longevity solutions
- Evidence‑backed consumer health innovation
This next phase of growth will enable Decode Age to operate at global research scale while delivering accessible, scientifically validated longevity solutions for consumers.
Collaborations Strengthening India’s Longevity Ecosystem
Decode Age contributes to India’s growing longevity ecosystem through collaborations with:
- Indian Institute of Science (IISc)
- Global longevity initiatives such as XPRIZE
These partnerships support microbiome‑linked data generation, analysis, and longevity medicine research, reinforcing the company’s commitment to scientifically robust, globally aligned ageing research.
A Strong Foundation for the Future
Since its inception in 2021, Decode Age has:
- Established advanced metagenomics and microbiome laboratories
- Introduced whole‑genome microbiome analysis for individuals
- Developed precision‑designed formulations informed by ageing biology
- Built an integrated longevity ecosystem connecting laboratories, clinicians, partners, and individuals
These milestones provide a strong foundation for the company’s next phase of research, scale, and global expansion.
About Decode Age
Decode Age is India’s first and leading science‑led longevity organisation dedicated to improving human healthspan through microbiome research, biomarker‑based testing, and precision‑focused interventions. Founded in 2021, the company integrates biotechnology, metagenomics, and computational biology to create research‑driven supplements and longevity solutions that support healthy ageing and make complex biology accessible and actionable for individuals and partners.
